Innovent Biologics, Inc. (HKG: 1801)
Hong Kong
· Delayed Price · Currency is HKD
48.85
+1.45 (3.06%)
Oct 10, 2024, 4:08 PM HKT
Innovent Biologics Revenue
Innovent Biologics had revenue of 3.95B CNY in the half year ending June 30, 2024, with 76.47% growth. This brings the company's revenue in the last twelve months to 7.46B, up 48.59% year-over-year. In the year 2023, Innovent Biologics had annual revenue of 6.21B with 36.21% growth.
Revenue (ttm)
7.46B CNY
Revenue Growth
+48.59%
P/S Ratio
9.78
Revenue / Employee
1.53M CNY
Employees
4,872
Market Cap
79.68B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionInnovent Biologics News
- 4 days ago - Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer - PRNewsWire
- 16 days ago - Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis - PRNewsWire
- 24 days ago - Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress - PRNewsWire
- 24 days ago - Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress - PRNewsWire
- 4 weeks ago - Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 - PRNewsWire
- 4 weeks ago - Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC - PRNewsWire
- 4 weeks ago - Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation - PRNewsWire
- 5 weeks ago - Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma - PRNewsWire